ExpiresMay 22, 2023
Louisiana Medical Mutual Insurance Company (LAMMICO)
The National Cancer Institute estimates over 76,000 new cases and 9,480 deaths due to melanoma in 2013. Public awareness of melanoma and diagnostic scrutiny has increased, and overdiagnosis has been described in the literature. New treatments promise to improve survival rates. But delayed or missed diagnosis of melanoma is still a life-threatening risk to the patient and the most common liability risk to the dermatologist. Data from medical malpractice claims, several review articles, and a clinical practice guideline suggest strategies for reducing this risk and improving diagnosis of melanoma.
Pre-and Post-test results are provided to diplomate and an evaluation survey is issued upon completion of the course. A follow-up post-activity survey is also issued 3-4 months after completion that asks what practice changes have been made.
ABMS Member Board Approvals by Type
ABMS MOC Part II CME Activity
NOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.
Describe several types of errors implicated in the delayed diagnosis of melanoma.
State the essential, recommended and optional data to provide to the pathologist with a biopsy specimen, according to the AAD melanoma guideline.
State recommended procedures for handling patient refusal of recommended treatment.
Delayed Diagnosis, Melanoma, Missed Diagnosis, Professional Liability, Diagnostic Error, Claims, Dermatology, Melanoma Guidelines
Interpersonal & Communication Skills, Medical Knowledge, Patient Care & Procedural Skills
CME Credit Type
AMA PRA Category 1 Credit
Academic Medicine, Outpatient, Rural, Urban, VA/Military
National Quality Strategies and/or Quadruple Aim Care Processes
Assessment, Patient Safety/Medical Errors, Evidence Based Practice